15:41 , Jul 18, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Peptides A fibrin matrix loaded with synthetic laminin peptides that bind growth factors could be used for wound healing and tissue regeneration applications. The peptides are 24- and 19-mer synthetic analogs of human laminin α...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

BioChaperone PDGF-BB: Development halted

Adocia said it will halt development of BioChaperone PDGF-BB to treat diabetic foot ulcers after top-line data from a double-blind, Indian Phase III trial in 252 patients showed that 4 ug/cm 2 BioChaperone PDGF-BB spray...
07:00 , Aug 26, 2016 |  BC Extra  |  Clinical News

Adocia halting diabetic foot ulcer programs after Phase III miss

Adocia S.A. (Euronext:ADOC) said its BioChaperone PDGF-BB spray missed the primary endpoint in an Indian Phase III study to treat diabetic foot ulcers. The candidate did not significantly improve complete wound closure after 20 weeks...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Tendoncel: Phase II data

A double-blind, placebo-controlled Phase II trial in 34 patients with chronic grade 3 lateral epicondylitis showed that once-daily topical Tendoncel for 21 days significantly improved DASH scores by 70% and PRTEE scores by 74%. Tendoncel...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Clinical News

Augment Bone Graft regulatory update

FDA issued an approvable letter to Wright Medical for a PMA for Augment Bone Graft for use as an alternative to autograft in hindfoot and ankle fusion procedures. Wright said it needs to address inspection...
08:00 , Nov 6, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Osteoporosis Platelet derived growth factor BB (PDGF-BB); cathepsin K (CTSK) In vitro and mouse studies suggest...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

BioChaperone PDGF-BB: Phase III started

Adocia began a double-blind, placebo-controlled, Indian Phase III trial to evaluate BioChaperone PDGF-BB spray in 252 Type I and II diabetics with a chronic foot ulcer. In 4Q15, the company also plans to start a...
07:00 , Mar 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Bone repair; wounds Bone morphogenetic protein 2 (BMP2); platelet-derived growth factor BB (PDGFBB); placental growth factor ...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Clinical News

BioChaperone PDGF-BB: Phase III start

Adocia said it received positive scientific advice from EMA for a placebo-controlled, European Phase III trial of BioChaperone PDGF-BB. The trial is slated to start mid-2014. According to Adocia, EMA said 1 European Phase III...